Financial Services

A new report reveals chronic underfunding and human error leave U.S. public services dangerously exposed to relentless ransomware and phishing attacks.

A new supply agreement for the rare isotope Actinium-225 between NorthStar and BIOEMTECH promises to break a critical bottleneck in radiopharmaceutical R&D.

As AI creates data bottlenecks, Lumen launches a new Multi-Cloud Gateway and metro network expansion, aiming to simplify hybrid IT and power innovation.

Landmark study in JAMA Neurology shows BRIUMVI offers near-zero relapse rates and stable disability, reshaping long-term multiple sclerosis treatment.

A new FDA approval allows a lung cancer therapy to be given just once a month, a major shift promising to reduce clinic time and improve quality of life.

With its burn treatment gaining traction and a pivotal wound care drug in late-stage trials, MediWound prepares to make its case to Wall Street.

TMD Energy's new director, a capital markets expert, sparks a 6.6% stock gain and speculation of M&A or major fundraising on the horizon.

Valmont Industries posts strong adjusted Q4 earnings, banking on a booming infrastructure segment to counter a deep agricultural slump and fuel growth in 2026.

Sanborn's Dr. Srini Dharmapuri has been named an ASPRS Fellow for his work on accuracy standards and digital twins, shaping the future of geospatial data.

With a major new partner and $20M in funding, Westhaven Gold kicks off a record 50,000m drill campaign to unlock its Shovelnose project in BC.

Now debt-free with $14M in cash, Castellum is leveraging major Navy contracts to fuel its next phase of expansion through acquisitions and innovation.

Bausch Health heads to a key finance conference to address investor concerns over its massive debt, upcoming patent cliffs, and future strategic direction.

Citing 'prolonged underperformance,' activist investor Starboard Value seeks to replace Tripadvisor's board, igniting a battle for control.

As Pasithea Therapeutics heads to a key investor conference, all eyes are on its lead drug, PAS-004, and its potential to treat rare and complex diseases.

A new therapy for a rare brain cancer is one step closer to patients after the FDA accepted tirabrutinib for accelerated review, offering hope where few options exist.

A strategic merger creates a new aerospace and defense giant, but existing shareholders face significant dilution in a deal laden with both promise and risk.

Landmark Phase 3 trial results show psilocybin offers rapid, lasting relief for severe depression, pushing psychedelic medicine closer to the mainstream.

Montréal defied a turbulent year, welcoming 11.8M visitors and securing $5.8B in spending. Now, it's gearing up for its biggest year since the Olympics.

New long-term data shows duvakitug maintained remission in IBD patients for nearly a year, positioning it as a top contender in a new class of therapy.

Salmon giant SalMar secures a new 10-year green bond, signaling strong investor confidence in its sustainable strategy despite a negative credit outlook.